CARLSBAD, Calif. / Apr 01, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture... Read More

Event Scheduled for June 26 and 27, 2024 CARLSBAD, Calif. / Mar 18, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation , a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by... Read More

CARLSBAD, Calif. / Mar 13, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to... Read More

CARLSBAD, Calif. / Mar 11, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 ( OpRegen ) will be presented at the 2024 Association for Research in Vision and... Read More

Advanced OpRegen ® For Dry AMD in Phase 2a Study in Collaboration with Roche and Genentech Closed $14 Million Registered Direct Offering OPC1 Investigational New Drug Amendment Cleared; New Clinical Trial Planned Initiated Development of Hypoimmune iPSC Cell Line for Neurology Indications Under Gene Editing Collaboration with Eterna Therapeutics Added to Russell 3000 ® Index Established 1 st Annual Spinal Cord Injury... Read More

CARLSBAD, Calif. / Feb 29, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets. Lineage management will also... Read More

The DOSED Clinical Study Will Evaluate a Novel Delivery Device in Subacute and Chronic Spinal Cord Injury Patients CARLSBAD, Calif. / Feb 13, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its... Read More

CARLSBAD, Calif. / Feb 09, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of 13,461,540 of the company’s common shares at an offering price of $1.04 per common share. The price... Read More

CARLSBAD, Calif. / Feb 06, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors for the purchase and sale of 13,461,540 of the company’s common shares in a registered direct offering at an offering price of... Read More

CARLSBAD, Calif. / Jan 16, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) in geographic atrophy (GA) secondary to... Read More

CARLSBAD, Calif. / Dec 18, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administration (FDA), for OPC1 , its investigational allogeneic oligodendrocyte progenitor cell... Read More

Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen ® ) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Under Management of Genentech, a Member of the Roche Group Additional RG6501 (OpRegen ® ) Data Presented at 23 rd Annual EURETINA Congress and 2023 Eyecelerator Meetings U.S. Patent Issued Covering Manufacturing and Differentiation Process for Retinal Pigment... Read More

CARLSBAD, Calif. / Nov 01, 2023 / Business Wire / Lineage Cell Therapeutics, Inc . (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a... Read More

Company Also Will Present at “Mapping the Future of Geographic Atrophy” Session at Eyecelerator@AAO 2023 CARLSBAD, Calif. / Oct 24, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, has been invited to present as part... Read More

CARLSBAD, Calif. / Oct 11, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”. The patent, which has been... Read More

CARLSBAD, Calif. / Oct 05, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses demonstrating rapid improvement in outer retinal structure from patients enrolled in a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov... Read More

CARLSBAD, Calif. / Sep 19, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Cantor Fitzgerald 2023 Global Healthcare Conference , in a fireside chat hosted by Kristen Kluska, Managing Director,... Read More

CARLSBAD, Calif. / Sep 13, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure from a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov Identifier:... Read More

CARLSBAD, Calif. / Sep 11, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Gary S. Hogge, D.V.M., M.S., Ph.D., Lineage’s Senior Vice President, Clinical & Medical Affairs, will present at the 2023 International Spinal Research Trust (ISRT) Network Meeting , being... Read More

CARLSBAD, Calif. / Sep 06, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, today announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company’s exclusive option... Read More

CARLSBAD, Calif. / Aug 29, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at Baird’s 2023 Global Healthcare Conference, in a fireside chat hosted by Jack K. Allen, CFA, Senior Research Analyst, Robert... Read More

Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen ® ) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group FDA Type B Meeting Response Provides Path for New OPC1 Delivery Device Positive Topline Data Reported from Phase 1 VAC2 Study for the Treatment of NSCLC Lineage Added to Russell 3000 ® Index Established and Presented 1 st Annual Spinal Cord Injury Investor... Read More

CARLSBAD, Calif. / Aug 03, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 10, 2023, following the close of the U.S. financial markets. Lineage management will also host a... Read More

Patients enrolled were diagnosed with refractory, metastatic or locally advanced, non-small cell lung cancer (NSCLC), for whom there were no other suitable treatment options Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated immune-related progressive disease No patients had treatment emergent serious adverse events and all patients completed per... Read More

CARLSBAD, Calif. / May 22, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the broad-market Russell 3000 ® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective as of the U.S. market open on June... Read More

Additional RG6501 (OpRegen ® ) Phase 1/2a Clinical Study Results Presented at ARVO 2023 Enrolling Phase 2a Clinical Study of RG6501 (OpRegen) in Patients with GA Secondary to AMD Under Management of Genentech, a Member of the Roche Group Awarded CIRM Grant to Support 1 st Annual Spinal Cord Injury Investor Symposium Signed Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune iPSC Lines Initiated... Read More

Award Will Support 1 st Annual Spinal Cord Injury Investor Symposium To Be Held June 29, 2023 CARLSBAD, Calif. / May 09, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received a grant from the California Institute for Regenerative Medicine (CIRM) ,... Read More

CARLSBAD, Calif. / May 04, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Lineage management will also host a... Read More

Preliminary Evidence of Durable Anatomical and Functional Improvements Following Administration of OpRegen Cells Extensive OpRegen Surgical Bleb Coverage of Areas of GA May Be Critical for Optimizing Patient Outcomes OCT Imaging With Segmentation Analysis is Advantageous in Assessment of Retinal Integrity Post-Treatment CARLSBAD, Calif. / Apr 26, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE:... Read More

CARLSBAD, Calif. / Apr 18, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the 2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference , on April 25 th , 2023... Read More

Inaugural Event on June 29, 2023, at the Sanford Consortium for Regenerative Medicine CARLSBAD, Calif. / Mar 30, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation , a non-profit organization dedicated to advancing innovative research and... Read More

CARLSBAD, Calif. / Mar 20, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 ( OpRegen ), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit , organized by the Foundation Fighting Blindness... Read More

CARLSBAD, Calif. / Mar 09, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the fourth quarter and full year ended December 31, 2022 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results. “2022 marked a... Read More

CARLSBAD, Calif. / Mar 06, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging analyses of structural changes in addition to visual data from a Phase 1/2a clinical study of RG6501 ( OpRegen ), will be presented at the 2023 Association for Research in... Read More

CARLSBAD, Calif. / Mar 02, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets. Lineage management will also... Read More

CARLSBAD, Calif. / Feb 22, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LC T X ), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Eterna Therapeutics Inc. (“Eterna”) for the development of novel... Read More

CARLSBAD, Calif. / Feb 08, 2023 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided an update on its auditory neuronal cell therapy program (ANP1), for the treatment of hearing loss, with an initial focus on auditory neuropathy spectrum disorders. Preclinical testing of ANP1 has... Read More